Lindsey Shapiro,  —

An analysis of genetic sequencing data has identified potential new biomarkers for diagnosing ankylosing spondylitis (AS). Specifically, scientists analyzed mRNAs, or the templates used to generate a protein from DNA, and found that the levels of three — Cxcr6, IL17RA, and Lrrfip1 — were associated with disease severity and…

Researchers have described a successful bone surgery to correct a rare type of spinal deformity in a man with ankylosing spondylitis (AS) that had prevented him from facing forward while walking — marking the first case report of this type of spinal surgery for an AS patient. While AS…

An eight-week Pilates group training program for people with ankylosing spondylitis (AS) lowered disease activity, improved spine flexibility, and led to gains in endurance, balance, and quality of life, a recent study showed. Several of these benefits were not seen among those who did an individual at-home exercise program,…

Diarrhea, cold-like symptoms, itchy skin, and rash are the most common real-world side effects associated with Cosentyx, an approved treatment for ankylosing spondylitis (AS), a study has found. Such side effects typically emerge in the first month of using the medication, according to the analysis, which included information…

Long-term treatment with under-the-skin injections of brodalumab safely and effectively reduced disease activity in people with axial spondyloarthritis (axSpA), according to final data from a Phase 3 trial. axSpA is a type of chronic inflammatory arthritis affecting the joints of the spine, chest, and pelvis. Ankylosing spondylitis (AS) is…

A new algorithm based on artificial intelligence (AI) could help clinicians reach an earlier diagnosis of akylosing spondylitis (AS), a study found. Using only demographic and clinical data derived from standard blood tests, the method does not require more costly and less widely available imaging techniques, researchers say. The algorithm…

The U.S. Food and Drug Administration (FDA) has approved a new, more highly concentrated formulation of Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira (adalimumab), for the treatment of ankylosing spondylitis. As a biosimilar, Hadlima has similar properties, safety, and efficacy to an approved biological treatment, in this…